Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Exploiting drug delivery systems for oral route in the peptic ulcer disease treatment

Full text
Author(s):
Sposito, Larissa [1] ; Fortunato, Giovanna Capaldi [2] ; de Camargo, Bruna Almeida Furquim [1] ; Ramos, Matheus Aparecido dos Santos [1] ; de Souza, Mauricio Palmeira Chaves [1] ; Meneguin, Andreia Bagliotti [1] ; Bauab, Tais Maria [2] ; Chorilli, Marlus [1]
Total Authors: 8
Affiliation:
[1] Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, Dept Drugs & Med, Rod Araraquara Jau, Km 01, BR-14800903 Araraquara, SP - Brazil
[2] Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, Dept Biol Sci, Araraquara, SP - Brazil
Total Affiliations: 2
Document type: Review article
Source: Journal of Drug Targeting; v. 29, n. 10, p. 1029-1047, NOV 26 2021.
Web of Science Citations: 0
Abstract

Peptic ulcer disease (PUD) is a common condition that is induced by acid and pepsin causing lesions in the mucosa of the duodenum and stomach. The pathogenesis of PUD is a many-sided scenario, which involves an imbalance between protective factors, such as prostaglandins, blood flow, and cell renewal, and aggressive ones, like alcohol abuse, smoking, Helicobacter pylori colonisation, and the use of non-steroidal anti-inflammatory drugs. The standard oral treatment is well established; however, several problems can decrease the success of this therapy, such as drug degradation in the gastric environment, low oral bioavailability, and lack of vectorisation to the target site. In this way, the use of strategies to improve the effectiveness of these conventional drugs becomes interesting. Currently, the use of drug delivery systems is being explored as an option to improve the drug therapy limitations, such as antimicrobial resistance, low bioavailability, molecule degradation in an acid environment, and low concentration of the drug at the site of action. This article provides a review of oral drug delivery systems looking for improving the treatment of PUD. (AU)

FAPESP's process: 19/09597-6 - Gastroretentive microparticles containing trans resveratrol nanoparticles applied to the treatment of Helicobacter pylori infections
Grantee:Larissa Sposito
Support Opportunities: Scholarships in Brazil - Doctorate